Regardless of revascularization or not , ticagrelor consistently reduced the primary outcome ( HR 0.86 vs. 0.85 , interaction P = 0.93 ) , and all-cause death ( HR 0.75 vs. 0.73 , interaction P = 0.89 ) with no significant increase in overall major bleeding .